Vanda ( (VNDA) ) has shared an update.
On March 14, 2025, Vanda Pharmaceuticals announced that the FDA has accepted its new drug application for tradipitant, aimed at treating motion sickness, with a decision expected by December 30, 2025. Despite successful trials showing significant efficacy in reducing motion-induced vomiting, Vanda criticized the FDA for delaying the review process, highlighting concerns about the agency’s impact on innovation and public health.
More about Vanda
Vanda Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative therapies to address unmet medical needs. The company primarily develops drugs for central nervous system disorders and other medical conditions.
YTD Price Performance: 3.32%
Average Trading Volume: 646,401
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $290.4M
For an in-depth examination of VNDA stock, go to TipRanks’ Stock Analysis page.